Study of gene changes in ASXL1-mutated myelofibrosis
Part of Blood & lymphatic clinical trials.
This study looks at how ASXL1 gene changes shape myelofibrosis over time. It may help doctors better understand the disease and potentially improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 years or older).
- You have health coverage through the French national social security system.
- Your myelofibrosis tests positive for an ASXL1 mutation (primary or secondary).
- You can sign an informed consent form to join the study.
- You are included in, or have agreed to be included in, France’s FIM clinical-biology database.
- You do not currently have another blood cancer or active blood disease at diagnosis.
- You are able to legally consent (not under legal protection that prevents consent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people diagnosed with myelofibrosis to understand how the disease affects them over time. It may help researchers learn more about the condition and improve future care.
This study follows people with myelofibrosis and anemia who are starting a new treatment. It aims to learn more about the disease and how treatments work in real life.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This study looks at how much of a specific gene change (CALR) you have, and whether it helps doctors diagnose and follow people with certain blood cancers over time. It mainly involves using samples and medical data rather than testing a new drug.
This study looks at how multiple myeloma (a bone marrow cancer) changes over time, especially why it becomes resistant to treatment or comes back. It may help researchers learn what drives relapse and could lead to better future treatments.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.